Key Takeaways:
- FDA regulations now explicitly recognize validated non-animal methods for drug safety testing.
- The rule removes animal testing as the assumed regulatory default but does not prohibit its use.
- Greater FDA acceptance of NAMs could accelerate non-animal testing technologies relevant to beauty.
The US Food and Drug Administration (FDA) is taking another step away from animal testing as the default in drug development, updating its regulations to explicitly recognize non-animal methods as acceptable options for generating safety evidence before products are tested in humans.
The agency issued a direct final rule on September 21, replacing references to “animal studies” across its regulations with broader terms “nonclinical tests” and “nonclinical studies.” The change removes language that could imply animal testing is the only acceptable route for generating safety information for drugs and biological products intended for human use.
Under the updated framework, developers can use New Approach Methodologies (NAMs), including human cell-based testing, organs-on-chips, computer modeling, and other emerging technologies where methods have been adequately validated and are appropriate for the product and regulatory question.
The rule does not ban animal testing or lower the evidence required by FDA. Animal studies can still be used where appropriate. Instead, the regulatory change gives developers greater flexibility over how they produce the evidence required to progress toward human clinical trials.
“This new rule supports the Trump Administration’s push to explore ways to complement, or where appropriate, replace animal studies...